| Cash Flow | 2025-07-31 |
|---|---|
| Common stock issued to consultants | 0 |
| Net loss | -8,306 |
| Stock option compensation to employees and directors | 2,822 |
| Stock options issued to consultants | 77 |
| Amortization of operating lease right-of-use asset | 27 |
| Amortization of discount on held-to-maturity securities | 93 |
| Receivables | -173 |
| Prepaid expenses and other current assets | 155 |
| Accounts payable | -249 |
| Accrued expenses | -195 |
| Operating lease liability | -19 |
| Net cash used in operating activities | -5,918 |
| Disbursements to acquire short-term investments | 36,700 |
| Proceeds from maturities of short-term investments | 40,912 |
| Net cash provided by investing activities | 4,212 |
| Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of 123 and 139, respectively | 1,924 |
| Proceeds from sale of common stock pursuant to an employee stock purchase plan | 4 |
| Proceeds from exercise of stock options | 2 |
| Net cash provided by financing activities | 1,930 |
| Net increase in cash and cash equivalents | 224 |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)